US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-01-19

AUTHORS

Sarita D. Boyd, LaRee Tracy, Takashi E. Komatsu, Patrick R. Harrington, Prabha Viswanathan, Jeff Murray, Adam Sherwat

ABSTRACT

Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall, the US Food and Drug Administration (FDA) encountered challenging regulatory issues due to the limitations of clinical trial data in certain subpopulations. In GT1a-infected subjects, baseline NS5A resistance-associated polymorphisms emerged as the strongest baseline characteristic associated with diminished SVR12 rates following 12 weeks of elbasvir/grazoprevir treatment. The decision for recommending 16 weeks of elbasvir/grazoprevir + ribavirin in this population and for extrapolating these recommendations to patients with advanced CKD was based on benefit-versus-risk analyses using the available data. Conversely, FDA had insufficient data to define a specific elbasvir/grazoprevir treatment regimen for GT1a-infected subjects with baseline NS5A resistance-associated polymorphisms who failed prior treatment with pegylated interferon + ribavirin (PR) and either boceprevir, simeprevir, or telaprevir. For GT4 PR-experienced patients, leveraging of data in related populations and additional pooled analyses were employed to support labeling for elbasvir/grazoprevir. This article describes FDA’s rationale for labeling determinations in situations where limited data made these decisions challenging. More... »

PAGES

317-326

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-017-0492-5

DOI

http://dx.doi.org/10.1007/s40261-017-0492-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053759688

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28102520


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzofurans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinoxalines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Insufficiency, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribavirin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyd", 
        "givenName": "Sarita D.", 
        "id": "sg:person.01357207237.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357207237.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tracy", 
        "givenName": "LaRee", 
        "id": "sg:person.01053306441.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053306441.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komatsu", 
        "givenName": "Takashi E.", 
        "id": "sg:person.01135363254.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135363254.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrington", 
        "givenName": "Patrick R.", 
        "id": "sg:person.0614215165.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614215165.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Viswanathan", 
        "givenName": "Prabha", 
        "id": "sg:person.01361264260.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361264260.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murray", 
        "givenName": "Jeff", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.483500.a", 
          "name": [
            "Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sherwat", 
        "givenName": "Adam", 
        "id": "sg:person.01023425257.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023425257.21"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-01-19", 
    "datePublishedReg": "2017-01-19", 
    "description": "Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12\u00a0weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall, the US Food and Drug Administration (FDA) encountered challenging regulatory issues due to the limitations of clinical trial data in certain subpopulations. In GT1a-infected subjects, baseline NS5A resistance-associated polymorphisms emerged as the strongest baseline characteristic associated with diminished SVR12 rates following 12\u00a0weeks of elbasvir/grazoprevir treatment. The decision for recommending 16\u00a0weeks of elbasvir/grazoprevir\u00a0+\u00a0ribavirin in this population and for extrapolating these recommendations to patients with advanced CKD was based on benefit-versus-risk analyses using the available data. Conversely, FDA had insufficient data to define a specific elbasvir/grazoprevir treatment regimen for GT1a-infected subjects with baseline NS5A resistance-associated polymorphisms who failed prior treatment with pegylated interferon\u00a0+\u00a0ribavirin (PR) and either boceprevir, simeprevir, or telaprevir. For GT4 PR-experienced patients, leveraging of data in related populations and additional pooled analyses were employed to support labeling for elbasvir/grazoprevir. This article describes FDA\u2019s rationale for labeling determinations in situations where limited data made these decisions challenging.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40261-017-0492-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "elbasvir/grazoprevir", 
      "chronic kidney disease", 
      "chronic hepatitis C virus genotype 1", 
      "hepatitis C virus genotype 1", 
      "elbasvir/grazoprevir treatment", 
      "advanced chronic kidney disease", 
      "C virus genotype 1", 
      "resistance-associated polymorphisms", 
      "genotype 1", 
      "end of treatment", 
      "clinical trial data", 
      "SVR12 rates", 
      "baseline characteristics", 
      "treatment regimen", 
      "kidney disease", 
      "pooled analysis", 
      "US FDA perspective", 
      "clinical trials", 
      "US Food", 
      "Drug Administration", 
      "prior treatment", 
      "trial data", 
      "certain subpopulations", 
      "patients", 
      "grazoprevir", 
      "weeks", 
      "limited data", 
      "ribavirin", 
      "treatment", 
      "FDA perspective", 
      "rate 12", 
      "insufficient data", 
      "favorable results", 
      "GT1a", 
      "subjects", 
      "polymorphism", 
      "regimen", 
      "boceprevir", 
      "simeprevir", 
      "telaprevir", 
      "population", 
      "interferon", 
      "infection", 
      "available data", 
      "disease", 
      "administration", 
      "trials", 
      "rationale", 
      "FDA", 
      "subpopulations", 
      "GT4", 
      "data", 
      "food", 
      "recommendations", 
      "labeling", 
      "regulatory issues", 
      "benefits", 
      "rate", 
      "analysis", 
      "risk analysis", 
      "decisions", 
      "end", 
      "results", 
      "limitations", 
      "characteristics", 
      "related populations", 
      "article", 
      "situation", 
      "perspective", 
      "issues", 
      "determination"
    ], 
    "name": "US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection", 
    "pagination": "317-326", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053759688"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-017-0492-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28102520"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-017-0492-5", 
      "https://app.dimensions.ai/details/publication/pub.1053759688"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_718.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40261-017-0492-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0492-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0492-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0492-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0492-5'


 

This table displays all metadata directly associated to this object as RDF triples.

223 TRIPLES      20 PREDICATES      107 URIs      99 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-017-0492-5 schema:about N02fc712d8ca143b8b49bd5f9374ab30d
2 N0d69bc3159a04667a0fba0e32644a99c
3 N15365b910dc546e1b6a5b3760fe4faaf
4 N23d492cd796249eaba35fb10204a66cc
5 N24da29f5b3764fa8ba2ac8ee4572ac64
6 N2702721415cb4b909b58a8374b4aa32d
7 N69b12c84e5d94ceab766c9b35c07d045
8 Nab10270632f64ff69624c61f49c147f4
9 Nabdca12629654b90933f87642664b039
10 Nced281e1b311483b8865abc132aaeeaa
11 Ne5a0062ee002449a848b4b3f7be120cc
12 Nf54e8bb2e7ae4edcb72e46f1c6497d94
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N84874ed7117045b1bfaade7c0b109dc3
16 schema:datePublished 2017-01-19
17 schema:datePublishedReg 2017-01-19
18 schema:description Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall, the US Food and Drug Administration (FDA) encountered challenging regulatory issues due to the limitations of clinical trial data in certain subpopulations. In GT1a-infected subjects, baseline NS5A resistance-associated polymorphisms emerged as the strongest baseline characteristic associated with diminished SVR12 rates following 12 weeks of elbasvir/grazoprevir treatment. The decision for recommending 16 weeks of elbasvir/grazoprevir + ribavirin in this population and for extrapolating these recommendations to patients with advanced CKD was based on benefit-versus-risk analyses using the available data. Conversely, FDA had insufficient data to define a specific elbasvir/grazoprevir treatment regimen for GT1a-infected subjects with baseline NS5A resistance-associated polymorphisms who failed prior treatment with pegylated interferon + ribavirin (PR) and either boceprevir, simeprevir, or telaprevir. For GT4 PR-experienced patients, leveraging of data in related populations and additional pooled analyses were employed to support labeling for elbasvir/grazoprevir. This article describes FDA’s rationale for labeling determinations in situations where limited data made these decisions challenging.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N5f7f48ec76a44baf8196fd8f8ddcc783
22 N6e1e15d5e9f84e37a80ddf918ff266a1
23 sg:journal.1100199
24 schema:keywords C virus genotype 1
25 Drug Administration
26 FDA
27 FDA perspective
28 GT1a
29 GT4
30 SVR12 rates
31 US FDA perspective
32 US Food
33 administration
34 advanced chronic kidney disease
35 analysis
36 article
37 available data
38 baseline characteristics
39 benefits
40 boceprevir
41 certain subpopulations
42 characteristics
43 chronic hepatitis C virus genotype 1
44 chronic kidney disease
45 clinical trial data
46 clinical trials
47 data
48 decisions
49 determination
50 disease
51 elbasvir/grazoprevir
52 elbasvir/grazoprevir treatment
53 end
54 end of treatment
55 favorable results
56 food
57 genotype 1
58 grazoprevir
59 hepatitis C virus genotype 1
60 infection
61 insufficient data
62 interferon
63 issues
64 kidney disease
65 labeling
66 limitations
67 limited data
68 patients
69 perspective
70 polymorphism
71 pooled analysis
72 population
73 prior treatment
74 rate
75 rate 12
76 rationale
77 recommendations
78 regimen
79 regulatory issues
80 related populations
81 resistance-associated polymorphisms
82 results
83 ribavirin
84 risk analysis
85 simeprevir
86 situation
87 subjects
88 subpopulations
89 telaprevir
90 treatment
91 treatment regimen
92 trial data
93 trials
94 weeks
95 schema:name US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
96 schema:pagination 317-326
97 schema:productId Na2158f5d930c47fb96964e38c8a7992b
98 Nd02ffae2fa3a4bba809034c26ec7bad4
99 Nf25a82572cf14c939a394e81985319a9
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053759688
101 https://doi.org/10.1007/s40261-017-0492-5
102 schema:sdDatePublished 2022-11-24T21:01
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N4ef9e1436312457ab8144cddd9709445
105 schema:url https://doi.org/10.1007/s40261-017-0492-5
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N02fc712d8ca143b8b49bd5f9374ab30d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Benzofurans
111 rdf:type schema:DefinedTerm
112 N0d69bc3159a04667a0fba0e32644a99c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Antiviral Agents
114 rdf:type schema:DefinedTerm
115 N15365b910dc546e1b6a5b3760fe4faaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Imidazoles
117 rdf:type schema:DefinedTerm
118 N23d492cd796249eaba35fb10204a66cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Quinoxalines
120 rdf:type schema:DefinedTerm
121 N24da29f5b3764fa8ba2ac8ee4572ac64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Hepatitis C, Chronic
123 rdf:type schema:DefinedTerm
124 N2702721415cb4b909b58a8374b4aa32d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Hepacivirus
126 rdf:type schema:DefinedTerm
127 N293d5aebbeca4eb895f9f46e051f6c88 rdf:first sg:person.01023425257.21
128 rdf:rest rdf:nil
129 N405fd13e5b5941c2b00507193269be3f schema:affiliation grid-institutes:grid.483500.a
130 schema:familyName Murray
131 schema:givenName Jeff
132 rdf:type schema:Person
133 N4e697dc657b1448cb32d6d624948c188 rdf:first sg:person.01135363254.69
134 rdf:rest Nb1e5e8dab72a435aa8c79332856c5889
135 N4e6e25417d434e11baa12ac9f92327f1 rdf:first N405fd13e5b5941c2b00507193269be3f
136 rdf:rest N293d5aebbeca4eb895f9f46e051f6c88
137 N4ef9e1436312457ab8144cddd9709445 schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N5f7f48ec76a44baf8196fd8f8ddcc783 schema:issueNumber 4
140 rdf:type schema:PublicationIssue
141 N69b12c84e5d94ceab766c9b35c07d045 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Ribavirin
143 rdf:type schema:DefinedTerm
144 N6e1e15d5e9f84e37a80ddf918ff266a1 schema:volumeNumber 37
145 rdf:type schema:PublicationVolume
146 N7c66a453c9084f98833a6feee2962c70 rdf:first sg:person.01361264260.11
147 rdf:rest N4e6e25417d434e11baa12ac9f92327f1
148 N84874ed7117045b1bfaade7c0b109dc3 rdf:first sg:person.01357207237.64
149 rdf:rest Na44b2768cb48462481c59f817cbd306c
150 Na2158f5d930c47fb96964e38c8a7992b schema:name dimensions_id
151 schema:value pub.1053759688
152 rdf:type schema:PropertyValue
153 Na44b2768cb48462481c59f817cbd306c rdf:first sg:person.01053306441.13
154 rdf:rest N4e697dc657b1448cb32d6d624948c188
155 Nab10270632f64ff69624c61f49c147f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Drug Combinations
157 rdf:type schema:DefinedTerm
158 Nabdca12629654b90933f87642664b039 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Treatment Outcome
160 rdf:type schema:DefinedTerm
161 Nb1e5e8dab72a435aa8c79332856c5889 rdf:first sg:person.0614215165.37
162 rdf:rest N7c66a453c9084f98833a6feee2962c70
163 Nced281e1b311483b8865abc132aaeeaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Humans
165 rdf:type schema:DefinedTerm
166 Nd02ffae2fa3a4bba809034c26ec7bad4 schema:name pubmed_id
167 schema:value 28102520
168 rdf:type schema:PropertyValue
169 Ne5a0062ee002449a848b4b3f7be120cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Genotype
171 rdf:type schema:DefinedTerm
172 Nf25a82572cf14c939a394e81985319a9 schema:name doi
173 schema:value 10.1007/s40261-017-0492-5
174 rdf:type schema:PropertyValue
175 Nf54e8bb2e7ae4edcb72e46f1c6497d94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Renal Insufficiency, Chronic
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
182 schema:name Clinical Sciences
183 rdf:type schema:DefinedTerm
184 sg:journal.1100199 schema:issn 1173-2563
185 1179-1918
186 schema:name Clinical Drug Investigation
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01023425257.21 schema:affiliation grid-institutes:grid.483500.a
190 schema:familyName Sherwat
191 schema:givenName Adam
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023425257.21
193 rdf:type schema:Person
194 sg:person.01053306441.13 schema:affiliation grid-institutes:grid.483500.a
195 schema:familyName Tracy
196 schema:givenName LaRee
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053306441.13
198 rdf:type schema:Person
199 sg:person.01135363254.69 schema:affiliation grid-institutes:grid.483500.a
200 schema:familyName Komatsu
201 schema:givenName Takashi E.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135363254.69
203 rdf:type schema:Person
204 sg:person.01357207237.64 schema:affiliation grid-institutes:grid.483500.a
205 schema:familyName Boyd
206 schema:givenName Sarita D.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357207237.64
208 rdf:type schema:Person
209 sg:person.01361264260.11 schema:affiliation grid-institutes:grid.483500.a
210 schema:familyName Viswanathan
211 schema:givenName Prabha
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361264260.11
213 rdf:type schema:Person
214 sg:person.0614215165.37 schema:affiliation grid-institutes:grid.483500.a
215 schema:familyName Harrington
216 schema:givenName Patrick R.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614215165.37
218 rdf:type schema:Person
219 grid-institutes:grid.483500.a schema:alternateName Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA
220 Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA
221 schema:name Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA
222 Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, 20993, Silver Spring, MD, USA
223 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...